Uncategorized

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting

Eli Lilly and Company announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent Bruton’s tyrosine kinase inhibitor, in adult patients with a range of B-cell malignancies.

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting Read More »

CSL Behring’s HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Global biotechnology leader CSL announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® following a one-time infusion in people living with hemophilia B.

CSL Behring’s HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B Read More »

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

Legend Biotech Corporation, a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced patient-reported outcome data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology Annual Meeting.

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel) Read More »

Scroll to Top